DOVATO

This brand name is authorized in Austria, Australia, Canada, Cyprus, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, United Kingdom, United States

Active ingredients

The drug DOVATO contains a combination of these active pharmaceutical ingredients (APIs):

1	Lamivudine UNII 2T8Q726O95 - LAMIVUDINE
	Lamivudine is a nucleoside analogue which has activity against human immunodeficiency virus (HIV) and hepatitis B virus (HBV). Its main mode of action is as a chain terminator of viral reverse transcription.
	Read more about Lamivudine
2	Dolutegravir UNII 1Q1V9V5WYQ - DOLUTEGRAVIR SODIUM
	Dolutegravir inhibits HIV integrase by binding to the integrase active site and blocking the strand transfer step of retroviral Deoxyribonucleic acid (DNA) integration which is essential for the HIV replication cycle.
	Read more about Dolutegravir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
DOVATO Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AR25	Lamivudine and dolutegravir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AR Antivirals for treatment of HIV infections, combinations
Discover more medicines within J05AR25

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11843H
CA	Health Products and Food Branch	02491753
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	6188-MEE-0421
EE	Ravimiamet	1799073, 1799084
ES	Centro de información online de medicamentos de la AEMPS	1191370001
FI	Lääkealan turvallisuus- ja kehittämiskeskus	423096
FR	Base de données publique des médicaments	67301231
GB	Medicines & Healthcare Products Regulatory Agency	374819
HK	Department of Health Drug Office	66511
IL	מִשְׂרַד הַבְּרִיאוּת	8505
JP	医薬品医療機器総合機構	6250119F1029
LT	Valstybinė vaistų kontrolės tarnyba	1088256, 1088257
NL	Z-Index G-Standaard, PRK	198692
NZ	Medicines and Medical Devices Safety Authority	21442
PL	Rejestru Produktów Leczniczych	100420992
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66226001
US	FDA, National Drug Code	49702-246